Revolution Medicines (RVMD) CEO Goldsmith sells $18 million in shares
Published on 4/17/2026
AI Summary
Summarized by AI from the source belowRevolution Medicines (RVMD) CEO Mark Goldsmith sold shares valued at $18 million. This sale reflects a significant transaction that may influence investor sentiment and perceptions of the company's future. The timing and volume of the sale could affect the stock's trading activity in the short term. Such insider trading activity is notable as it can signal confidence or potential shifts in strategy within the company.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
